Press Releases

Press Releases

Date Title
11/12/19 Vaxart Announces Third Quarter 2019 Financial Results and Provides Corporate Update
- $9 million Underwritten Public Offering Closed - - Oral Bivalent Norovirus Vaccine Meets Primary and Secondary Endpoints in Phase 1b Study - SOUTH SAN FRANCISCO, Calif. , Nov. 12, 2019 (GLOBE NEWSWIRE) -- Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines
11/06/19 Vaxart Hosting Key Opinion Leader Meeting on the Health Economics of Norovirus Disease
Norovirus represents a $3+billion U.S. market opportunity SOUTH SAN FRANCISCO, Calif. , Nov. 06, 2019 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced
10/28/19 Vaxart, Inc. Announces Changes to its Board of Directors
The company has appointed four new members to the Board of Directors SOUTH SAN FRANCISCO, Calif. , Oct. 28, 2019 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection,
10/01/19 Vaxart to Present Clinical Data From its Norovirus Phase 1b Study at Three Global Healthcare Conferences in October 2019
ID Week (Washington, DC), 7th International Calicivirus Conference (Sydney, AU) and the 10th International Vaccines for Enteric Diseases (Lausanne, CH)   SOUTH SAN FRANCISCO, Calif. , Oct. 01, 2019 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing
09/26/19 Vaxart Announces Pricing of $8 Million Underwritten Public Offering
SOUTH SAN FRANCISCO, Calif. , Sept. 26, 2019 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biopharmaceutical company focused on the development of oral recombinant vaccines based on its proprietary oral vaccine platform, today announced the pricing of an underwritten public
09/25/19 Vaxart’s Tableted Oral Bivalent Norovirus Vaccine Meets Primary and Secondary Endpoints in Phase 1b Study
Both norovirus vaccines induced substantial immune responses with no indication of immunological interference when administered concurrently Phase 2-ready oral norovirus vaccine targets potential $3B+ market opportunity SOUTH SAN FRANCISCO, Calif. , Sept. 25, 2019 (GLOBE NEWSWIRE) -- Vaxart, Inc.
09/04/19 Vaxart to Present at the H.C. Wainwright 21st Annual Global Investment Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 4, 2019-- Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Wouter Latour , M.D., president and chief executive officer of
08/08/19 Vaxart Announces Second Quarter 2019 Financial Results and Provides Corporate Update
- Phase 1b Bivalent Norovirus Study Fully Enrolled - - Research Collaboration with Janssen for Universal Flu Vaccine Underway - SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 8, 2019-- Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are
07/09/19 Vaxart Enters into Research Collaboration with Janssen to Evaluate Oral Universal Influenza Vaccine
Oral Universal Flu Vaccine Candidate to be Evaluated in Pre-Clinical Challenge Model SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 9, 2019-- Vaxart, Inc. , ( Vaxart ), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by
06/20/19 Vaxart to Present at ASM Microbe 2019
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 20, 2019-- Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Roberto Mateo , Ph.D., senior scientist at Vaxart ,